Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age

OBJECTIVES: To characterize the clinical course and outcomes of children 12-18 years of age who developed probable myopericarditis after vaccination with the Pfizer-BioNTech (BNT162b2) coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine. STUDY DESIGN: A cross-sectional study of 25 child...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Bibhuti B., Kohli, Utkarsh, Ramachandran, Preeti, Nguyen, Hoang H., Greil, Gerald, Hussain, Tarique, Tandon, Animesh, Kane, Colin, Avula, Sravani, Duru, Chioma, Hede, Sannya, Sharma, Kavita, Chowdhury, Devyani, Patel, Sunil, Mercer, Christopher, Chaudhuri, Nita Ray, Patel, Bhavi, Ang, Jocelyn Y., Asmar, Basim, Sanchez, Joselito, Khan, Danyal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321962/
https://www.ncbi.nlm.nih.gov/pubmed/34339728
http://dx.doi.org/10.1016/j.jpeds.2021.07.044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321962/
https://www.ncbi.nlm.nih.gov/pubmed/34339728
http://dx.doi.org/10.1016/j.jpeds.2021.07.044

Ejemplares similares